Abstract
The accumulation of sphingolipids, including sphingomyelin and glycosphingolipids, in atherosclerotic lesions is well known. Plasma sphingomyelin concentration is correlated with atherosclerosis development and is an independent predictor of coronary artery disease. Similarly, plasma glycosphingolipid levels are increased in conditions associated with atherosclerosis risk. Recent studies have focused on understanding the mechanisms by which specific intermediates and end-products of the sphingolipid biosynthetic pathway, such as sphingomyelin, glycosphingolipids, ceramide and sphingosine-1-phosphate may modulate vascular biology and atherosclerosis. Here we focus on recent work indicating that pharmacological modulation of the sphingolipid biosynthetic pathway could offer a novel treatment for atherosclerosis or, at the very least, provide mechanistic insights concerning the eitiology of this disease which is the major cause of death in developed countries.
Keywords: Atherosclerosis, sphingomyelin, glycosphingolipids, ceramide kinase, ceramide-1-phosphate, myriocin, sphingolipid, inhibitors, ABCA-1
Current Vascular Pharmacology
Title: Fine Tuning Therapeutic Targeting of the Sphingolipid Biosynthetic Pathway to Treat Atherosclerosis
Volume: 4 Issue: 2
Author(s): W. S. Kim, Charles E. Chalfant and Brett Garner
Affiliation:
Keywords: Atherosclerosis, sphingomyelin, glycosphingolipids, ceramide kinase, ceramide-1-phosphate, myriocin, sphingolipid, inhibitors, ABCA-1
Abstract: The accumulation of sphingolipids, including sphingomyelin and glycosphingolipids, in atherosclerotic lesions is well known. Plasma sphingomyelin concentration is correlated with atherosclerosis development and is an independent predictor of coronary artery disease. Similarly, plasma glycosphingolipid levels are increased in conditions associated with atherosclerosis risk. Recent studies have focused on understanding the mechanisms by which specific intermediates and end-products of the sphingolipid biosynthetic pathway, such as sphingomyelin, glycosphingolipids, ceramide and sphingosine-1-phosphate may modulate vascular biology and atherosclerosis. Here we focus on recent work indicating that pharmacological modulation of the sphingolipid biosynthetic pathway could offer a novel treatment for atherosclerosis or, at the very least, provide mechanistic insights concerning the eitiology of this disease which is the major cause of death in developed countries.
Export Options
About this article
Cite this article as:
Kim S. W., Chalfant E. Charles and Garner Brett, Fine Tuning Therapeutic Targeting of the Sphingolipid Biosynthetic Pathway to Treat Atherosclerosis, Current Vascular Pharmacology 2006; 4 (2) . https://dx.doi.org/10.2174/157016106776359844
DOI https://dx.doi.org/10.2174/157016106776359844 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications
Current Medicinal Chemistry A Historical Overview on Coronary Surgery and Interventional Cardiology: Parallel Pathways?
Vascular Disease Prevention (Discontinued) Vitamins and Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets New Antihypertensive Drugs Under Development
Current Medicinal Chemistry Oxidative Stress and Cardiac Remodeling: An Updated Edge
Current Cardiology Reviews Patent Selections:
Recent Patents on Biomedical Engineering (Discontinued) Modulation of Ion Channels in Pulmonary Arterial Hypertension
Current Pharmaceutical Design Nigella Sativa Improve Redox Homeostasis in Heart and Aorta of Diabetic Rat
Current Nutrition & Food Science Teratological Consequences of Nitric Oxide Synthesis Inhibition
Current Pharmaceutical Design Oral Anticoagulation in Atrial Fibrillation
Cardiovascular & Hematological Agents in Medicinal Chemistry Biological Relevance of Lysophospholipids and Green Solutions for Their Synthesis
Current Organic Chemistry Relationship between Hyperlipidemia, Cardiovascular Disease and Stroke: A Systematic Review
Current Cardiology Reviews Mitochondria as Possible Pharmaceutical Targets for the Effects of Vitamin E and its Homologues in Oxidative Stress-Related Diseases
Current Pharmaceutical Design Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts
Current Vascular Pharmacology Safety and Efficacy of Aliskiren in the Treatment of Hypertension and Associated Clinical Conditions
Current Drug Safety Aortic Arch Calcification and Mortality in Chronic Hemodialysis Patients
Reviews on Recent Clinical Trials Type 1 11 β-hydroxysteroid Dehydrogenase as Universal Drug Target in Metabolic Diseases?
Endocrine, Metabolic & Immune Disorders - Drug Targets The Diabetic Charcot Foot
Current Diabetes Reviews Hypoxia and Oxidative Stress in the Causation of Diabetic Retinopathy
Current Diabetes Reviews Translational Application of In Vivo Imaging and Analysis of Atherosclerotic Plaque Vulnerability Assessment
Recent Patents on Medical Imaging